文献速递前列腺癌

比卡鲁胺联合或不联合二甲双胍治疗超重或肥胖前列腺癌生化复发患者的随机2期研究(BIMET-1)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-25

这项开放标签随机2期试验纳入29例非糖尿病、生化复发、PSADT 3-9个月、BMI>25且睾酮正常的前列腺癌患者,1:2随机分为先观察8周(A组)或二甲双胍1000 mg每日两次(B组),8周后两组均加用比卡鲁胺50 mg/日。主要终点为32周时PSA不可测(<0.2 ng/mL)的患者数,两组无差异;二甲双胍单药使40.0%患者PSA轻度下降4%-24%。试验因预测无法达到主要终点而提前终止。

要点

  • 二甲双胍联合比卡鲁胺耐受性良好,但32周PSA不可测率较单用比卡鲁胺无改善。
  • 二甲双胍单药8周后40.0%(95%CI 19.1-64.0%)患者PSA轻度下降4%-24%。
  • 二甲双胍单药及联合比卡鲁胺均显示以NK细胞和T细胞亚群为主的免疫调节效应。

核心结论

  • 二甲双胍联合比卡鲁胺耐受性良好,但32周时PSA不可测率无改善。
  • 二甲双胍单药8周后使40%患者出现轻度PSA下降。
  • 二甲双胍单药及联合比卡鲁胺均显示以NK细胞和T细胞亚群为主的免疫调节效应。

研究设计与样本

  • 开放标签、随机、2期试验(NCT02614859),纳入非糖尿病、生化复发前列腺癌患者,PSADT 3-9个月、BMI>25且睾酮正常。
  • 患者1:2随机分为先观察8周(A组)或二甲双胍1000 mg每日两次(B组),8周后两组均加用比卡鲁胺50 mg/日。
  • 主要目标为评估32周结束时PSA不可测(<0.2 ng/mL)的患者数,免疫相关指标为探索性终点。
  • 2015年3月至2020年1月共纳入29例患者。

主要发现

  • 两组PSA不可测患者比例无差异。
  • 二甲双胍单药组40.0%(95%CI:19.1-64.0%)患者PSA轻度下降4%-24%,观察组为11.1%(95%CI:0.3-48.3%)。
  • 二甲双胍单药减少PD-1+ NK细胞并增加NKG2D+ NK细胞。
  • 二甲双胍联合比卡鲁胺较单用比卡鲁胺使PD-1表达NK细胞、CD4+ T细胞和CD8+ T细胞亚群下降更明显。
  • 试验因预测无法达到主要终点而提前终止。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验因预测无法达到主要终点而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin may have anticancer effects that are independent of its hypoglycemic effects. Retrospective studies have shown that metformin use is associated with decreased incidence of prostate cancer and prostate cancer-specific mortality. Preclinical studies suggesting additive anticancer effects of combining metformin and bicalutamide prompted this clinical trial (NCT02614859). METHODS: This open-label, randomized, phase 2 trial enrolled non-diabetic patients with biochemically recurrent prostate cancer, a PSADT of 3-9 months, BMI > 25 and normal testosterone. Patients were randomized 1:2 to observation for an initial 8 weeks (Arm A) or metformin 1000 mg twice daily (Arm B). Bicalutamide 50 mg/day was added after 8 weeks to both arms. The primary objective was to evaluate the number of patients with undetectable PSA ( < 0.2 ng/mL) at the end of 32 weeks. Immune correlatives were assessed as exploratory endpoints. RESULTS: A total of 29 patients were enrolled from March 2015 to January 2020. No difference was seen between the 2 arms in the proportion of patients with undetectable PSA. Modest PSA decrease ranging from 4% to 24% were seen in 40.0% (95% CI: 19.1-64.0%) of patients with metformin monotherapy, compared to 11.1% (95% CI: 0.3-48.3%) in the observation arm. Metformin monotherapy reduced PD-1+ NK cells, and increased NKG2D+ NK cells. The combination of metformin and bicalutamide led to greater reductions in PD-1 expressing NK, CD4+ T, and CD8+ T-cell subsets compared to bicalutamide alone. The trial was stopped early due to predicted inability to achieve its primary endpoint. CONCLUSIONS: Although metformin plus bicalutamide was well tolerated, there was no improvement in rates of achieving undetectable PSA at 32 weeks. Metformin monotherapy induced modest PSA declines in 40% of patients after 8 weeks. Metformin, given alone and in combination with bicalutamide, displayed immune modifying effects, primarily within NK and T cells subsets. TRIAL REGISTRATION: Trial Registration Number: NCT02614859.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bilusic M, Toney NJ, Donahue RN, et al. A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer Prostatic Dis. 2022. PMID: 35079115. doi:10.1038/s41391-022-00492-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。